Results for tag: "Uterine Fibroid Embolization Device"

In the sphere of women's health, uterine fibroid embolization devices hold an important role in the treatment of uterine fibroids, which are noncancerous growths of the uterus that often appear during childbearing years. Uterine Fibroid Embolization (UFE) is a minimally invasive procedure that serves as an alternative to hysterectomy or myomectomy for patients seeking relief from the symptoms produced by fibroids, such as heavy menstrual bleeding and pelvic pressure. In this procedure, a specialized device is used by interventional radiologists to deliver embolic agents that occlude the arteries supplying blood to the fibroids, leading to their shrinkage and symptom alleviation. The UFE procedure has become increasingly popular due to its effectiveness and because it spares the uterus, presenting a less invasive option compared to surgical interventions and allowing for a quicker recovery time. The choice of embolization devices and materials is carefully considered to optimize patient outcomes while minimizing potential complications. As different providers exist in the market, they consistently innovate to develop more advanced embolization products, ensuring safety, enhancing precision, and improving the patient experience. Leading companies in the uterine fibroid embolization device market include Merit Medical Systems, Boston Scientific Corporation, Cook Medical, Terumo Corporation, Medtronic, and Johnson & Johnson. These enterprises are at the forefront of medical device technology, offering a variety of options tailored for the UFE procedure to meet the diverse needs of Show Less Read more